Incyte (INCY) Interest Expenses (2010 - 2026)
Incyte's (INCY) quarterly Interest Expenses came in at $6.3 million in Q2 2026, up 10.53% YoY from $5.7 million in Q2 2025, and down 1.56% on a QoQ basis from $6.4 million in Q1 2026.
Incyte (INCY) Interest Expenses (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Interest Expenses data on file, last reported at $6.3 million in Q2 2026.
- Quarterly Interest Expenses rose 10.53% year-over-year to $6.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.6 million (down 107.35% YoY) and the FY2025 annual result came in at $22.4 million, down 98.95% from the prior year.
- Interest Expenses fell to $6.3 million in Q2 2026, from $6.4 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $6.4 million in Q1 2026 to a low of -$14.9 million in Q4 2025.
- A 5-year average of $2.7 million and a median of $5.0 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses plunged 1906.45% — and 2024, when it jumped 139.84%.
- Tracing INCY's Interest Expenses over 5 years: stood at $667000.0 in 2022, then sank by 1906.45% to -$12.0 million in 2023, then surged by 139.84% to $4.8 million in 2024, then sank by 409.83% to -$14.9 million in 2025, then surged by 142.36% to $6.3 million in 2026.
- The last three Interest Expenses figures came in at $6.3 million (Q2 2026), $6.4 million (Q1 2026), and -$14.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 6.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.30 Mn |
| Jun 30, 2026 | 6.30 Mn |
| Mar 31, 2026 | 6.40 Mn |
| Mar 31, 2026 | 6.40 Mn |
| Dec 31, 2025 | -14.87 Mn |
| Dec 31, 2025 | -14.87 Mn |
| Sep 30, 2025 | 592,000.00 |
| Sep 30, 2025 | 592,000.00 |
| Jun 30, 2025 | 5.70 Mn |
| Jun 30, 2025 | 5.70 Mn |
| Mar 31, 2025 | 5.80 Mn |
| Mar 31, 2025 | 5.80 Mn |
| Dec 31, 2024 | 4.80 Mn |
| Dec 31, 2024 | 4.80 Mn |
| Sep 30, 2024 | 5.20 Mn |
| Sep 30, 2024 | 5.20 Mn |
| Jun 30, 2024 | 5.20 Mn |
| Jun 30, 2024 | 5.20 Mn |
| Mar 31, 2024 | 5.40 Mn |
| Mar 31, 2024 | 5.40 Mn |